TABLE 2.

Parkinson’s disease clinical characteristics.

Age at diagnosis, (years) [SD, range]*	58.8 [13.6, 24–88]
Parkinson’s disease duration, (years) [SD, range]*	9.2 [6.5, 1–30]
Parkinson’s disease phenotype, (%)*
Tremor Dominant	30.1
Postural Instability and gait Impairment	20.4
Akinetic rigid	38.9
Young onset (<40years)	10.7
Late onset (>60years)	49.5
Genetic diagnosis, (%)*	1.9
Disease complications, (%)*
Motor fluctuations	58.3
Dyskinesia	58.3
Wearing off	81.6
Impulse control disorder	19.4
Non-motor symptoms, (%)*
Hyposmia	73.8
REM sleep behavior disorder	48.5
Constipation	60.2
Levodopa equivalent daily dose (mg), [SD, range]*	834.8 [527.3, 0–2,186]
MDS unified Parkinson’s disease rating scale-III (“on” state), [SD, range]*	32.9 [17.7, 5–91]
Quality of life
PDQ-39 summary index, [SD]	29.2 [17.3]
MDS Non-motor symptoms score (NMSS)—total score, [SD]*	62.7 [42.9]
Parkinson’s disease therapy, (%)*
Treatment naïve	(n = 5) 4.9
Oral levodopa	(n = 92) 89.3
Dopamine agonist	(n = 36) 35.0
Monoamine oxidase B inhibitor	(n = 19) 18.4
Anticholinergic	(n = 13) 12.6
Catechol-O-methyl transferase inhibitor	(n = 24) 23.3
Amantadine	(n = 13) 12.6
Levodopa-carbidopa intestinal gel (LCIG)	(n = 9) 8.7
Deep brain stimulation	(n = 11) 10.7
Apomorphine (subcutaneous infusion)	(n = 7) 6.8

SD, (Standard Deviation). *This data is partially reproduced (Lubomski et al., 2020b).